Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial comparing recombinant human rabies immunoglobulin versus human rabies immunoglobulin with rabies vaccine
ChiCTR1900021478Phase 3Not yet recruiting
- Sponsor
- Yunnan Center for Disease Control and Prevention
- Start
- Mar 2019
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ormutivimab, rabies immune globulin (human) and human rabies vaccine in rabies (2 arms), sponsored by Yunnan Center for Disease Control and Prevention. Primary endpoint: Neutralizing antibody activity. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
ormutivimabrabies immune globulin (human)human rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR1900021478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021478.